US Bancorp DE Sells 106 Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB)

US Bancorp DE cut its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 10.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 892 shares of the medical instruments supplier’s stock after selling 106 shares during the quarter. US Bancorp DE’s holdings in Mesa Laboratories were worth $118,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Mesa Laboratories by 20.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,103 shares of the medical instruments supplier’s stock valued at $1,312,000 after purchasing an additional 1,708 shares during the period. Barclays PLC raised its stake in shares of Mesa Laboratories by 357.4% during the 3rd quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier’s stock valued at $1,148,000 after purchasing an additional 6,905 shares during the period. Geode Capital Management LLC raised its stake in shares of Mesa Laboratories by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 124,761 shares of the medical instruments supplier’s stock valued at $16,205,000 after purchasing an additional 5,771 shares during the period. Victory Capital Management Inc. raised its stake in shares of Mesa Laboratories by 90.3% during the 3rd quarter. Victory Capital Management Inc. now owns 14,001 shares of the medical instruments supplier’s stock valued at $1,818,000 after purchasing an additional 6,643 shares during the period. Finally, Franklin Resources Inc. raised its stake in shares of Mesa Laboratories by 27.8% during the 3rd quarter. Franklin Resources Inc. now owns 6,444 shares of the medical instruments supplier’s stock valued at $828,000 after purchasing an additional 1,403 shares during the period. 90.60% of the stock is currently owned by institutional investors.

Mesa Laboratories Stock Performance

NASDAQ:MLAB opened at $126.18 on Monday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.53 and a current ratio of 0.71. Mesa Laboratories, Inc. has a 52-week low of $83.68 and a 52-week high of $155.12. The firm has a market cap of $685.66 million, a price-to-earnings ratio of -2.73 and a beta of 0.82. The business’s fifty day moving average is $139.38 and its 200 day moving average is $129.32.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings data on Tuesday, February 4th. The medical instruments supplier reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.66. Mesa Laboratories had a positive return on equity of 30.23% and a negative net margin of 104.92%. Research analysts predict that Mesa Laboratories, Inc. will post 8 EPS for the current year.

Mesa Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Friday, February 28th will be paid a $0.16 dividend. The ex-dividend date is Friday, February 28th. This represents a $0.64 dividend on an annualized basis and a yield of 0.51%. Mesa Laboratories’s dividend payout ratio is currently -1.38%.

Mesa Laboratories Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.